Markets:

Overview

News

Currencies

International

Treasuries

Nuvalent, Inc. - Class A Common Stock (NQ:NUVL)

123.00 +34.51 (+39.00%)

Streaming Delayed Price Updated: 11:41 AM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nuvalent, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

Which stocks are gapping on Tuesday? ↗

Today 10:30 EDT

Via Chartmill

NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders

Today 9:05 EDT

From Halper Sadeh LLC

Via Business Wire

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

Today 8:30 EDT

Via Chartmill

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Topics Regulatory Compliance

Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones ↗

May 07, 2026

Via Chartmill

Topics Earnings

Why Did Nuvalent Stock Surge 15% Today? ↗

November 17, 2025

Via Stocktwits

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Via The Motley Fool

Topics Regulatory Compliance

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 17, 2025

Via Benzinga

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer ↗

November 17, 2025

Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.

Via Benzinga

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer ↗

November 17, 2025

Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug.

Via Investor's Business Daily

Wondering what's happening in today's after-hours session? ↗

November 14, 2025

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

This Waste Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

November 12, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.